233 related articles for article (PubMed ID: 23225121)
1. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
van der Pas R; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Webb SM; Lamberts SW; Hofland LJ; Feelders RA
Pituitary; 2013 Dec; 16(4):536-44. PubMed ID: 23225121
[TBL] [Abstract][Full Text] [Related]
2. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
van der Pas R; de Bruin C; Leebeek FW; de Maat MP; Rijken DC; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Lamberts SW; Hofland LJ; Feelders RA
J Clin Endocrinol Metab; 2012 Apr; 97(4):1303-10. PubMed ID: 22278425
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?
Barbot M; Albiger N; Ceccato F; Zilio M; Frigo AC; Denaro L; Mantero F; Scaroni C
Pituitary; 2014 Apr; 17(2):109-17. PubMed ID: 23468128
[TBL] [Abstract][Full Text] [Related]
4. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
Burman P; Edén-Engström B; Ekman B; Karlsson FA; Schwarcz E; Wahlberg J
Eur J Endocrinol; 2016 Jan; 174(1):17-24. PubMed ID: 26582653
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
Feelders RA; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; van Heerebeek R; de Jong FH; van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
N Engl J Med; 2010 May; 362(19):1846-8. PubMed ID: 20463350
[No Abstract] [Full Text] [Related]
6. Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.
Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Polenta B; Spinello M; Boscaro M; Arnaldi G
Pituitary; 2015 Feb; 18(1):60-7. PubMed ID: 24482099
[TBL] [Abstract][Full Text] [Related]
7. Update in the medical therapy of Cushing's disease.
Nieman LK
Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):330-4. PubMed ID: 23807605
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.
Vilar L; Naves LA; Azevedo MF; Arruda MJ; Arahata CM; Moura E Silva L; Agra R; Pontes L; Montenegro L; Albuquerque JL; Canadas V
Pituitary; 2010 Jun; 13(2):123-9. PubMed ID: 19943118
[TBL] [Abstract][Full Text] [Related]
9. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
10. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
Pivonello R; De Martino MC; Cappabianca P; De Leo M; Faggiano A; Lombardi G; Hofland LJ; Lamberts SW; Colao A
J Clin Endocrinol Metab; 2009 Jan; 94(1):223-30. PubMed ID: 18957500
[TBL] [Abstract][Full Text] [Related]
11. Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy.
van der Pas R; van Esch JH; de Bruin C; Danser AH; Pereira AM; Zelissen PM; Netea-Maier R; Sprij-Mooij DM; van den Berg-Garrelds IM; van Schaik RH; Lamberts SW; van den Meiracker AH; Hofland LJ; Feelders RA
Eur J Endocrinol; 2014 Feb; 170(2):181-91. PubMed ID: 24165019
[TBL] [Abstract][Full Text] [Related]
12. Psychometric evaluation of the Cushing's Quality-of-Life questionnaire.
Nelson LM; Forsythe A; McLeod L; Pulgar S; Maldonado M; Coles T; Zhang Y; Webb SM; Badia X
Patient; 2013; 6(2):113-24. PubMed ID: 23575965
[TBL] [Abstract][Full Text] [Related]
13. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.
Webb SM; Ware JE; Forsythe A; Yang M; Badia X; Nelson LM; Signorovitch JE; McLeod L; Maldonado M; Zgliczynski W; de Block C; Portocarrero-Ortiz L; Gadelha M
Eur J Endocrinol; 2014 Jul; 171(1):89-98. PubMed ID: 24760537
[TBL] [Abstract][Full Text] [Related]
14. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Findling JW; Fleseriu M; Newell-Price J; Petersenn S; Pivonello R; Kandra A; Pedroncelli AM; Biller BM
Endocrine; 2016 Nov; 54(2):516-523. PubMed ID: 27209465
[TBL] [Abstract][Full Text] [Related]
15. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
16. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
Newell-Price J; Pivonello R; Tabarin A; Fleseriu M; Witek P; Gadelha MR; Petersenn S; Tauchmanova L; Ravichandran S; Gupta P; Lacroix A; Biller BMK
Eur J Endocrinol; 2020 Feb; 182(2):207-217. PubMed ID: 31804965
[TBL] [Abstract][Full Text] [Related]
17. Remission with cabergoline in adolescent boys with Cushing's disease.
Güven A; Baltacıoğlu F; Dursun F; Cebeci AN; Kırmızıbekmez H
J Clin Res Pediatr Endocrinol; 2013 Sep; 5(3):194-8. PubMed ID: 24072089
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline for Cushing's disease: a large retrospective multicenter study.
Ferriere A; Cortet C; Chanson P; Delemer B; Caron P; Chabre O; Reznik Y; Bertherat J; Rohmer V; Briet C; Raingeard I; Castinetti F; Beckers A; Vroonen L; Maiter D; Cephise-Velayoudom FL; Nunes ML; Haissaguerre M; Tabarin A
Eur J Endocrinol; 2017 Mar; 176(3):305-314. PubMed ID: 28007845
[TBL] [Abstract][Full Text] [Related]
19. Pituitary-targeted medical therapy of Cushing's disease.
Alexandraki KI; Grossman AB
Expert Opin Investig Drugs; 2008 May; 17(5):669-77. PubMed ID: 18447593
[TBL] [Abstract][Full Text] [Related]
20. Medical therapy of Cushing's disease: where are we now?
Alexandraki KI; Grossman AB
Front Horm Res; 2010; 38():165-173. PubMed ID: 20616508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
